2Mary. V, wahl F, Uzan A, et al. Enoxaparin in experimented stroke neuropro- lection and therapeutic window of opportunity[J]. Stroke ,2001,32:993-999.
5Barber PA, Auer RN, Buchan AM,et al. Understanding and managing ischemic stroke[J]. Can J Physiol pharmcol,2001 ,79:283-296.
6Molitch ME,DeFronzo RA,Franz MJ,et al.Nephropathy in diabetes[J].Diabetes Care,2004,27(Suppl 1):S79-83.
7Young BA,Katon WJ,von Korff M,et al.Racial and ethnic differences in microalbuminuria prevalence in a diabetes population:the pathways study[J].J Am Soc Nephrol,2005,16(1):219-228.
8Jugdutt BI,Idikio H,Uwiera RR.Angiotensin receptor blockade and angiotensinconverting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction[J].Mol Cell Biochem,2007,303(1-2):27-38.
9Gashti CN,Badris GL.The role of calcium antagonists in chronic kidney disease[J].Curr Opin Nephrol Hypertens,2004,13:155-161.
